Bone Biologics Corporation

NasdaqCM BBLG

Bone Biologics Corporation Dividend Yield on February 06, 2025

Bone Biologics Corporation Dividend Yield is NA on February 06, 2025, a NA change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Bone Biologics Corporation 52-week high Dividend Yield is NA on February 06, 2025, which is NA below the current Dividend Yield.
Bone Biologics Corporation 52-week low Dividend Yield is NA on February 06, 2025, which is NA below the current Dividend Yield.
Bone Biologics Corporation average Dividend Yield for the last 52 weeks is NA.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

NasdaqCM: BBLG

Bone Biologics Corporation

CEO	Mr. Jeffrey Frelick
IPO Date	Oct. 13, 2021
Location	United States
Headquarters	2 Burlington Woods Drive
Employees	2
Sector	Technology
Industries 3D Printing Biotechnology Clinical Trials Composite Materials Medical Instruments Plastics Robotics

Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Key trends

Past 5 years